ZYDUS WELLNESS LTD.-$ - 531335 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Details of Voting Results at the 28th Annual General Meeting of the Company pursuant to regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ZYDUS WELLNESS LTD.-$ - 531335 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Combined Scrutinizer''s Report for remote e-voting and e-voting at the AGM ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the unaudited financial results for the quarter ended on June 30, 2022 Q1FY23 Quarterly Result Announced for Zydus Wellness Ltd.
Packaged Foods firm Zydus Wellness Announced Q1FY23 Result : Zydus Wellness Ltd, Net sales up by 17.8% Zydus Wellness Ltd. reported consolidated Net sales of Rs.693 crores, up by 17.8% and consolidated revenue from operations of Rs. 697 crores, up by 16.6%. Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 148 crores was up by 5.5% on a YoY basis. Adjusted Net profit before exceptional items for the quarter was up by 7% at Rs.140 crores. Reported Net profit for the quarter was up by 4.7% at Rs.137 crores. During the quarter gone by the Company witnessed resurgence in demand of summer oriented brands i.e. Glucon-D and Nycil. With strong distribution and marketing efforts, the Company could also re-recruit the consumers for these brands as a result of which they have registered a strong double digit growth. The key brands of the Company, like Sugar Free, Everyuth peel off, Everyuth scrub, Glucon-D and Nycil have maintained leadership position in their respective categories. Result PDF ZYDUS WELLNESS LTD.-$ - 531335 - Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On June 30, 2022
Standalone and Consolidated Unaudited Financial Results for the quarter ended on June 30, 2022 ZYDUS WELLNESS LTD.-$ - 531335 - Appointment of Company Secretary and Compliance Officer
Appointment of Mr. Nandish P. Joshi as the Company Secretary and Compliance Officer of the Company w.e.f. July 29, 2022
Zydus Lifesciences gets USFDA nod to market generic high blood pressure drug
Bisoprolol Fumarate Tablets are used to treat high blood pressure either alone or in combination with other high blood pressure medications. ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst / Institutional Investors' call
Zydus gets USFDA nod to market generic blood pressure lowering drug
The drug will be manufactured at the group's topical injectable manufacturing facility at Jarod, Gujarat, Zydus Lifesciences said.
